Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Teva Pharmaceutical Industries (Allegra Distribution Rights)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Portfolio of drug-distribution rights under the Allegra brand. The portfolio is comprised of exclusive U.S. store brand rights to sell and distribute OTC versions of Fexofenadine HCl 180 mg and 60 mg tabs, plus Fexofenadine HCl 60 mg and Pseudoephedrine 120 mg tabs, the generic versions of Sanofi -Aventis' Allegra and Allegra D-12 products.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Services (B2C Non-Financial)
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • 5 Basel Street
  • PO Box 3190 Petach
  • Tikva
  • Israel

Teva Pharmaceutical Industries (Allegra Distribution Rights) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Teva Pharmaceutical Industries (Allegra Distribution Rights)‘s full profile, request access.

Request full access to PitchBook

Teva Pharmaceutical Industries (Allegra Distribution Rights) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Teva Pharmaceutical Industries (Allegra Distribution Rights)‘s full profile, request access.

Request full access to PitchBook